Developing therapies for heart failure withpreservedejection fraction. Current state and future directions

Javed Butler*, Gregg C. Fonarow, Michael R. Zile, Carolyn S. Lam, Lothar Roessig, Erik B. Schelbert, Sanjiv J Shah, Ali Ahmed, Robert O Bonow, John G.F. Cleland, Robert J. Cody, Ovidiu Chioncel, Sean P. Collins, Preston Dunnmon, Gerasimos Filippatos, Martin P. Lefkowitz, Catherine N. Marti, John J. McMurray, Frank Misselwitz, Savina NodariChristopher O'Connor, Marc A. Pfeffer, Burkert Pieske, Bertram Pitt, Giuseppe Rosano, Hani N. Sabbah, Michele Senni, Scott D. Solomon, Norman Stockbridge, John R. Teerlink, Vasiliki V. Georgiopoulou, Mihai Gheorghiade

*Corresponding author for this work

Research output: Contribution to journalReview article

191 Scopus citations

Abstract

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.

Original languageEnglish (US)
Pages (from-to)97-112
Number of pages16
JournalJACC: Heart Failure
Volume2
Issue number2
DOIs
StatePublished - Apr 2014

Keywords

  • Epidemiology
  • Heart failure
  • Preserved ejection fraction
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Developing therapies for heart failure withpreservedejection fraction. Current state and future directions'. Together they form a unique fingerprint.

  • Cite this

    Butler, J., Fonarow, G. C., Zile, M. R., Lam, C. S., Roessig, L., Schelbert, E. B., Shah, S. J., Ahmed, A., Bonow, R. O., Cleland, J. G. F., Cody, R. J., Chioncel, O., Collins, S. P., Dunnmon, P., Filippatos, G., Lefkowitz, M. P., Marti, C. N., McMurray, J. J., Misselwitz, F., ... Gheorghiade, M. (2014). Developing therapies for heart failure withpreservedejection fraction. Current state and future directions. JACC: Heart Failure, 2(2), 97-112. https://doi.org/10.1016/j.jchf.2013.10.006